An observational study in Endometrial Carcinoma, sponsored by Azienda USL Reggio Emilia - IRCCS. Active, not recruiting at 8 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Azienda USL Reggio Emilia - IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Endometrial Neoplasms with a site in Italy — 70 open to participants now, 87 under way, 16 of them phase 3. Endometrial Neoplasms · Italy.
Among the 139 studies in Endometrial Neoplasms with a site in Italy, this one is the 9th largest by planned enrollment of the 42 observational ones that give a count, is one of 14 that started in 2021, is one of 42 observational ones, reaches primary completion later than 33 of the 86 other live ones, and was the 112th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →70 of the 139 studies in Endometrial Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+ · Women only
Eikon Therapeutics · Sites in Italy, United States, Australia and 12 more countries
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 21–75 · Women only
Genmab · Sites in Italy, United States, Australia and 16 more countries
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 39 · Phase 3 27 · Phase 4 1
First in 1988; this study’s year is marked. 14 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 179 across 331 observational studies indexed under Endometrial Neoplasms.
Median enrollment 290 across the 96 interventional studies, 200 across the 42 observational. Of the 40 that completed or were terminated, 11 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 139 have an industry lead sponsor. The 10 most frequent:
Azienda USL Reggio Emilia - IRCCS is the lead sponsor of 93 studies on the registry; 24 are open to participants now.
Azienda USL Reggio Emilia - IRCCS has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
19 of the studies in Endometrial Neoplasms with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT06790004Azienda USL Reggio Emilia - IRCCSEndometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy) | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06963385Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoRadiomics and Molecular Classification in Endometrial Cancer | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 139 studies in Endometrial Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Since the publication of the LAP2 study, a prospective randomized trial, laparoscopy has been considered the gold standard for treating patients with early-stage endometrial cancer (EC). However, no prospective randomized trials have been published reporting comparable data in patients with EC at high risk of recurrence (advanced stages or non-endometrioid histology). Nonetheless, some retrospective studies and a systematic review of the literature have demonstrated that minimally invasive surgery achieves better perioperative outcomes than laparotomy without compromising survival in patients with EC at high risk of recurrence.
The aim of this multicenter retrospective observational study is to evaluate the safety of minimally invasive surgery in treating EC at low, intermediate, and high risk of recurrence according to the ESMO-ESGO classification, based on cases treated in hospitals within the Emilia Romagna region. Specifically, we aim to assess the effects of a minimally invasive surgical approach compared to laparotomy in terms of:
This comparison will include patients treated for both endometrioid and non-endometrioid EC to provide a comprehensive evaluation of minimally invasive surgery versus laparotomy.
By delineating the safety and efficacy of laparoscopic techniques, particularly for higher-risk patients, this research could refine surgical standards and guide clinical decision-making, emphasizing evidence-based practices for tailored patient care. The study also aligns with broader efforts to optimize cancer management in regional and national healthcare settings.
Patients who underwent laparoscopic or laparotomic surgery for Type I or Type II endometrial cancer in the Emilia-Romagna region between 2000 and 2020
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients with endometrial cancer who underwent surgical treatment from 2000 to 2020 at all participating centers in Emilia-Romagna.
Procedure: Laparotomy · Procedure: Laparoscopy
Open Surgery
Minimally invasive surgery
Perioperative Complications
This metric assesses the number of participants with perioperative complications in the two intervention groups, specifically including the need for blood transfusions (either intraoperative or postoperative), surgery duration exceeding 180 minutes, postoperative fever \>38°C lasting more than 48 hours, and hospitalization exceeding 7 days.
Time frame: 30 days post-surgery.
Overall Survival (OS)
Death from Any Cause
Time frame: Five years post-surgery (from the date of surgery up to 5 years)
Disease-Free Survival (DFS)
Time from Surgery to First Disease Recurrence or Death
Time frame: Five years post-surgery (from the date of surgery up to 5 years)
Pattern of recurrence
Evaluation of the sites of recurrence, including pelvic relapse, lymph node relapse, and distant metastasis, with documentation of the timing of occurrence
Time frame: Five years post-surgery (from the date of surgery up to 5 years)
Complete Cytoreduction
Assessment of complete surgical cytoreduction, defined as the absence of visible residual disease at the conclusion of surgery
Time frame: Time of surgery
Plan to share: No
Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda USL Reggio Emilia - IRCCS